Showing 5731-5740 of 6808 results for "".
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://practicaldermatology.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2457597/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- Kuleana Debuts Natural, Reef-Safe Sunscreenhttps://practicaldermatology.com/news/kuleana-debuts-natural-reef-safe-sunscreen/2457601/Amid growing concerns that certain sunscreen ingredients are harming coral reefs and marine life, Hawaiian company Kuleana is rolling out a natural sunscreen that is free from oxybenzone and octinoxate – two chemicals known to be toxic to corals and other marine life that were recently bann
- New Laser Handpiece Clears Multicolor Tattoos in Fewer Treatmentshttps://practicaldermatology.com/news/new-laser-handpiece-clears-multicolor-tattoos-in-fewer-treatments/2457613/A new titanium sapphire laser handpiece can clear green, blue, and purple tattoo pigments in fewer treatments, according to a new study in Lasers in Surgery and Medicine (LSM). Researchers led by American Soc
- Foamix: Positive Topline Phase 3 Results for Topical Minocycline Foamhttps://practicaldermatology.com/news/foamix-positive-topline-phase-3-results-for-topical-minocycline-foam/2457614/Foamix Pharmaceuticals’ FMX101 topical minocycline foam for the treatment of moderate-to-severe acne has met primary endpoints of its third Phase 3 clinical trial. Foamix shared topline results of the clinical trial (FX2017-22), which met both co-prim
- Mayo Clinic Doctors Receive Stand Up to Cancer Catalyst Award for Melanoma Researchhttps://practicaldermatology.com/news/mayo-clinic-doctors-receive-stand-up-to-cancer-catalyst-award-for-melanoma-research/2457617/Mayo Clinic immunologist and medical oncologist Matthew Block, M.D., Ph.D. and surgeon Tina Hieken, M.D., received a
- Carpe: New Antiperspirant Twice As Effective As "Extra Strength"https://practicaldermatology.com/news/carpe-new-antiperspirant-twice-as-effective-as-extra-strength/2457623/Carpe’s newly launched underarm antiperspirant has been demonstrated to reduce sweat twice as effectively as the US legal standard for extra strength antiperspirants, the company says. While federal regulation requires that an extra strength antiperspirant demonstrate at least a 30% r
- Canfield Scientific Acquires Leading German Dermoscopy Company VISIOMED AGhttps://practicaldermatology.com/news/canfield-scientific-acquires-leading-german-dermoscopy-company-visiomed-ag/2457621/Canfield Scientific has acquired German company VISIOMED AG, which designs and manufactures dermoscopy systems. The resulting business has decades of experience in aesthetic documentation, 3D imaging, clinical photography, and reflected light microscopy leading to more choices and services for cu
- Compulink Launches Advantage SMART Practice Suite of AI Solutionshttps://practicaldermatology.com/news/compulink-launches-advantage-smart-practice-suite-of-ai-solutions/2457629/Compulink Healthcare Solutions rolled out new artificial intelligence (AI)-enabled features in a release its calling Advantage SMART Practice. Advantage uses AI technology and real-time data from the clinic to completely automate tasks such as billing, along with eliminating steps to improve pati
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- General Medicine Update: Daily Aspirin May Not Work Wonders After Allhttps://practicaldermatology.com/news/general-medicine-update-daily-aspirin-may-not-work-wonders-after-all/2457633/It remains unclear whether daily aspirin lowers the risk of a cardiovascular event in individuals at moderate risk of a first heart attack or stroke, according to late-breaking results from the ARRIVE study presented at the European Society of Cardiology (ESC) Congress 2018 a